State Street Corp Arcus Biosciences, Inc. Transaction History

State Street Corp

$2.36 Trillion
Q1 2025

A detailed history of State Street Corp transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, State Street Corp holds 3,696,479 shares of RCUS stock, worth $31.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,696,479

Previous 2,993,729 23.47%

Holding current value

$31.3 Million

Previous $44.6 Million 34.9%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$7.85 - $15.24 $5.52 Million - $10.7 Million	702,750 Added 23.47%	3,696,479 $29 Million
Q4 2024 Feb 14, 2025	SELL	$14.28 - $18.44 $249,114 - $321,685	-17,445 Reduced 0.58%	2,993,729 $44.6 Million
Q3 2024 Nov 14, 2024	SELL	$13.69 - $18.01 $600,744 - $790,314	-43,882 Reduced 1.44%	3,011,174 $46 Million
Q2 2024 Aug 14, 2024	SELL	$14.59 - $18.48 $27 Million - $34.2 Million	-1,849,457 Reduced 37.71%	3,055,056 $46.5 Million
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $9.86 Million - $13.4 Million	664,936 Added 15.68%	4,904,513 $92.6 Million
Q4 2023 Feb 14, 2024	BUY	$13.43 - $19.63 $531,196 - $776,425	39,553 Added 0.94%	4,239,577 $81 Million
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $2.51 Million - $3.35 Million	-142,224 Reduced 3.28%	4,200,024 $75.4 Million
Q2 2023 Aug 14, 2023	SELL	$16.97 - $22.03 $19.6 Million - $25.4 Million	-1,154,005 Reduced 21.0%	4,342,248 $88.2 Million
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $31.2 Million - $45.2 Million	1,951,970 Added 55.07%	5,496,253 $100 Million
Q4 2022 Feb 14, 2023	SELL	$19.7 - $35.71 $11.8 Million - $21.3 Million	-597,777 Reduced 14.43%	3,544,283 $73.3 Million
Q3 2022 Nov 15, 2022	SELL	$23.23 - $30.07 $6.82 Million - $8.83 Million	-293,789 Reduced 6.62%	4,142,060 $108 Million
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $29 Million - $63.6 Million	1,685,930 Added 61.31%	4,435,849 $112 Million
Q1 2022 May 16, 2022	BUY	$28.92 - $41.83 $16.1 Million - $23.3 Million	557,988 Added 25.46%	2,749,919 $86.8 Million
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $4.38 Million - $6.77 Million	-139,699 Reduced 5.99%	2,191,931 $88.7 Million
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $9.54 Million - $13.3 Million	-354,071 Reduced 13.18%	2,331,630 $81.3 Million
Q2 2021 Aug 16, 2021	BUY	$22.75 - $35.77 $11.8 Million - $18.6 Million	520,307 Added 24.03%	2,685,701 $73.7 Million
Q1 2021 May 17, 2021	BUY	$26.16 - $41.39 $8.96 Million - $14.2 Million	342,539 Added 18.79%	2,165,394 $60.8 Million
Q4 2020 Feb 16, 2021	SELL	$17.0 - $32.36 $11.8 Million - $22.5 Million	-695,613 Reduced 27.62%	1,822,855 $47.3 Million
Q3 2020 Nov 10, 2020	BUY	$17.14 - $25.47 $16 Million - $23.7 Million	930,969 Added 58.64%	2,518,468 $43.2 Million
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $13.2 Million - $34.5 Million	943,962 Added 146.68%	1,587,499 $39.3 Million
Q1 2020 May 11, 2020	BUY	$8.78 - $19.28 $5.65 Million - $12.4 Million	643,537 New	643,537 $8.93 Million

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

63.1M

Call Options Held

116K

Put Options Held

116K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $611M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Arcus Biosciences, Inc. Transaction History